Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
| Status: |
Suspended
|
| Expected date of issue: |
TBC |
| Referral date: |
November 2011 |
| Process: |
STA |
| Notes:
Scoped within Batch 20.
|
| Topic area:
|
NICE project team
| Executive Lead: |
TBC
|
| Technical Lead: |
Richard Diaz
|
| Communications manager: |
Alice Law
|
| Project manager: |
Lori Farrar
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
Consultees and commentators
Project history
| Date |
Update |
| 28 November 2013 |
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for denosumab in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
|
| 17 April 2013 |
The manufacturer of Denosumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal. |
|
Key documents
This page was last updated: 04 March 2014
